By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com
Share
Aa
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis News > Cannabis Press Releases > Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com
Cannabis Press Releases

Cannabis-Induced psychosis (CIP) Epidemiology Forecast Research Report 2022-2032 – ResearchAndMarkets.com

MJP Editors
Last updated: 2022/05/30 at 7:30 AM
MJP Editors Published March 15, 2022
Share
SHARE

DUBLIN–(BUSINESS WIRE)–The “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

logo Cannabis Media & PR

This “Cannabis-Induced psychosis (CIP) – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Cannabis-Induced psychosis (CIP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cannabis-Induced psychosis (CIP) Understanding

The Cannabis-Induced psychosis (CIP) epidemiology report gives a thorough understanding of the Cannabis-Induced psychosis (CIP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cannabis-Induced psychosis (CIP) in the US, Europe, and Japan. The report covers the detailed information of the Cannabis-Induced psychosis (CIP) epidemiology scenario in seven major countries (US, EU5, and Japan).

Cannabis-Induced psychosis (CIP) Epidemiology Perspective

The Cannabis-Induced psychosis (CIP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cannabis-Induced psychosis (CIP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.

The Cannabis-Induced psychosis (CIP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Cannabis-Induced psychosis (CIP) Detailed Epidemiology Segmentation

The Cannabis-Induced psychosis (CIP) epidemiology covered in the report provides historical as well as forecasted Cannabis-Induced psychosis (CIP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Cannabis-Induced psychosis (CIP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Report Highlights

  • 11-year Forecast of Cannabis-Induced psychosis (CIP) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Cannabis-Induced psychosis (CIP)
  • Cases of Cannabis-Induced psychosis (CIP) by Mutation Types
  • Cannabis-Induced psychosis (CIP) Cases associated with Clinical Manifestations

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1. Key Insights

2. Executive Summary of Cannabis-Induced psychosis (CIP)

3. Cannabis-Induced psychosis (CIP): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the 7MM (2019-2032)

5.4. United States Epidemiology

5.4.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the United States (2019-2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.2. France Epidemiology

5.5.3. Italy Epidemiology

5.5.4. Spain Epidemiology

5.5.5. United Kingdom Epidemiology

5.6. Japan Epidemiology

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Cannabis-Induced psychosis (CIP) Treatment and Management

6.2. Cannabis-Induced psychosis (CIP) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/73t5zp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

You Might Also Like

 Flower One Obtains Meeting Order Under the Companies’ Creditors Arrangement Act (Canada)

United States Alternative Adult Beverages Market Report 2022: The Burgeoning Adult Beverage Segment Expanding the Adult Beverage Horizon – ResearchAndMarkets.com

Global Cannabidiol Market Report 2022: Growing Acceptance and Use of Products Due to Government Approvals Drives Sector – ResearchAndMarkets.com

Organigram Launches HOLY MOUNTAIN to Further Support Its Strong Position in the Dried Flower and Hash Categories

Leafly to Participate at Upcoming Investor Conferences

TAGGED: Business Wire
MJP Editors March 15, 2022
Share this Article
Twitter Reddit Email Copy Link
Previous Article Healthtech Company Veriheal Releases Gender-Focused Medical Cannabis Preference Report
Next Article Fentanyl – Not Just an Opioid Problem – Warns Caron Treatment Centers

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Media KitNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US

© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.

  • Ad Choices
  • RSS Terms of Service
Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?